Abstract 10P
Background
As a result of a significant decrease in smoking prevalence in many countries, the overall incidence of head and neck squamous cell carcinoma (HNSCC) is declining. However, there is a growing recognition of an increased incidence of oral tongue squamous cell carcinoma (OTSCC) in non-smokers and non-drinkers (NSND) for reasons that are yet to be fully understood. OTSCC in NSND and smoker-drinker (SD) individuals have different molecular profiles, as well as distinct immune microenvironments, which may affect their susceptibility to targeted therapies and immunotherapy. The prognostic value of tumor-infiltrating lymphocytes (TILs) and tertiary lymphoid structures (TLS) in localized oral tongue squamous cell carcinoma (OTSCC) remains unclear. This study investigates the prognostic impact of TILs and TLS on recurrence in patients with surgically treated OTSCC in NSND.
Methods
A total of 100 patients with OTSCC underwent complete surgical resection at a single institution with a median follow-up of 35 months (IQR 12-60). TIL presence (minimal, moderate, heavy) and TLS maturation (aggregate, primary follicle, secondary follicle) were graded using brightfield H&E slides according to previously published criteria. The prognostic impact of TILs and TLS on survival was analyzed using multivariable Cox regression, adjusting for prognostic factors (tumor size, depth of invasion, grade, and surgical margin status). Multivariable logistic regression was used to evaluate these factors for associations with early recurrence (≤12 months).
Results
Heavy TIL presence was observed in 41% of cases, and TLS was present in 76%, of which 23% were mature. The presence of mature TLS was associated with reduced odds of early recurrence [OR 0.18, P=0.04], and the presence of heavy TILs was associated with improved overall survival (OS) [HR 0.26, P=0.02]. Tumors categorized as TIL-/TLS- were associated with significantly worse OS [HR 3.5, P=0.02] compared to tumors with heavy TILs or mature TLS.
Conclusions
TILs and mature TLS are independently associated with decreased rate of early recurrence for high-risk localized OTSCC. Further studies should validate these potential low-cost biomarkers.
Editorial acknowledgement
During the preparation of this work the author(s) used Chat GPT in order to checking grammar. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
156P - Liver Metastases Correlate with Shortened Survival and Increased Dissociate Response in Patients Treated with T-Cell Engagers.
Presenter: Noé Herbel
Session: Poster Display session
Resources:
Abstract
157P - Preliminary results of a multicentric randomized phase I/IIa trial of an immunotherapy targeting dendritic cells (DC), CD40HVac, in patients with HPV16-positive oropharyngeal carcinoma (OPC)
Presenter: Caroline Even
Session: Poster Display session
Resources:
Abstract
158P - XCR1+ dendritic cell (DC) role in antitumoral response to anti PD-L1 antibody: Data from the phase Ib/II trial of DC vaccination in small cell lung cancer patients
Presenter: Maria Gonzalez Cao
Session: Poster Display session
Resources:
Abstract
159P - Unveiling the impact of DC vaccination on systemic immunity in advanced malignant melanoma: Preliminary results from the ABSIDE study
Presenter: Giada Sabatino
Session: Poster Display session
Resources:
Abstract
160P - Oral DNA vaccination targeting personalised neoantigens in immune checkpoint-inhibitor treated solid tumor patients: Interim results
Presenter: Domas Vaitiekus
Session: Poster Display session
Resources:
Abstract
161P - Safety of TrimelVax vaccine for patients with advanced melanoma: Clinical results
Presenter: ROBERTO ESTAY
Session: Poster Display session
Resources:
Abstract
162P - EO4010 (EO) + nivolumab (N) ± bevacizumab (B) in patients (pts) with microsatellite stable (MSS) metastatic colorectal carcinoma (mCRC)
Presenter: Romain Cohen
Session: Poster Display session
Resources:
Abstract
163P - Effect of split intravenous dosing of oncolytic adenovirus TILT-123 on normal tissue versus tumor macrophages and virus bioavailability in patients with advanced solid tumors
Presenter: Elise Jirovec
Session: Poster Display session
Resources:
Abstract
164P - Roginolisib (IOA-244), the first highly selective oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3K_), has immuno-modulatory effects associated with clinical benefits in patients with metastatic uveal melanoma
Presenter: Anna Di Giacomo
Session: Poster Display session
Resources:
Abstract
165P - TIGIT inhibition in non-small cell lung cancer: Meta-analysis of clinical efficacy and biomarker correlation
Presenter: Hashim Talib Hashim
Session: Poster Display session
Resources:
Abstract